TY - JOUR
T1 - Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma
T2 - A pediatric oncology group study
AU - Douglass, E. G.
AU - Reynolds, M.
AU - Finegold, M.
AU - Cantor, A. B.
AU - Glicksman, A.
N1 - Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 1993
Y1 - 1993
N2 - Purpose: To estimate the disease-free survival rate in children with grossly resected hepatoblastoma treated with cisplatin, vincristine, and fluorouracil (CDDP/VCR/ FU) and to assess the disease-response rate and disease-free survival (DPS) rate in children with unresectable or metastatic tumors treated with this combination. Patients and Methods: Sixty assessable patients with hepatoblastoma received therapy with five (stage I and II) to seven (stage III and IV) courses of CDDP (90 mg/ m2), day 1, and VCR (1.5 mg/m2), and FU (600 mg/m2), day 3. Results: Nineteen of 21 patients with stage I or II disease survive free of disease (actuarial survival, 90% at 5 years). Twenty-four of 31 patients with stage III disease achieved a complete remission (CR) after chemotherapy and surgical excision; actuarial DPS at 4 years is 67%. Only one of eight patients with stage IV disease achieved a remission and survives. Conclusion: Relatively brief exposure to chemotherapy with CDDP/VCR/FU provided excellent disease control to patients with grossly resected tumors. In patients with initially unresectable disease, this therapy provides a response rate and DPS rate comparable to regimens that contain doxorubicin (DOX).
AB - Purpose: To estimate the disease-free survival rate in children with grossly resected hepatoblastoma treated with cisplatin, vincristine, and fluorouracil (CDDP/VCR/ FU) and to assess the disease-response rate and disease-free survival (DPS) rate in children with unresectable or metastatic tumors treated with this combination. Patients and Methods: Sixty assessable patients with hepatoblastoma received therapy with five (stage I and II) to seven (stage III and IV) courses of CDDP (90 mg/ m2), day 1, and VCR (1.5 mg/m2), and FU (600 mg/m2), day 3. Results: Nineteen of 21 patients with stage I or II disease survive free of disease (actuarial survival, 90% at 5 years). Twenty-four of 31 patients with stage III disease achieved a complete remission (CR) after chemotherapy and surgical excision; actuarial DPS at 4 years is 67%. Only one of eight patients with stage IV disease achieved a remission and survives. Conclusion: Relatively brief exposure to chemotherapy with CDDP/VCR/FU provided excellent disease control to patients with grossly resected tumors. In patients with initially unresectable disease, this therapy provides a response rate and DPS rate comparable to regimens that contain doxorubicin (DOX).
UR - http://www.scopus.com/inward/record.url?scp=0027522718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027522718&partnerID=8YFLogxK
U2 - 10.1200/JCO.1993.11.1.96
DO - 10.1200/JCO.1993.11.1.96
M3 - Article
C2 - 8380296
AN - SCOPUS:0027522718
VL - 11
SP - 96
EP - 99
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 1
ER -